Immunitybio is trading at $8.72, up 5.25%, amid biotech sector strength. - XBI was up 2.13%, while major U.S. indexes also rose sharply. - On November 4, Immunitybio announced that the first European patients received Anktiva plus BCG in Germany and Austria. The report noted shares were 1% higher when published, but did not establish the announcement as the cause of the later move. - No trading-volume information was provided.